[go: up one dir, main page]

MX2019011491A - Formulaciones de niraparib. - Google Patents

Formulaciones de niraparib.

Info

Publication number
MX2019011491A
MX2019011491A MX2019011491A MX2019011491A MX2019011491A MX 2019011491 A MX2019011491 A MX 2019011491A MX 2019011491 A MX2019011491 A MX 2019011491A MX 2019011491 A MX2019011491 A MX 2019011491A MX 2019011491 A MX2019011491 A MX 2019011491A
Authority
MX
Mexico
Prior art keywords
niraparib
capsule formulations
capsule
methods
formulations
Prior art date
Application number
MX2019011491A
Other languages
English (en)
Inventor
Mcgurk Simon
Narayan Padma
Medendorp Clare
Wu George
Ruddy Stephen
Kempinski Heidi
Stewart Alistair
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MX2019011491A publication Critical patent/MX2019011491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones de cápsulas farmacéuticas que comprenden el compuesto niraparib como principio farmacéutico activo, adecuadas para administración oral así como a métodos para su preparación; también se describen formulaciones de cápsulas que contienen niraparib formadas por los métodos descritos, y usos terapéuticos de tales formulaciones de cápsulas para tratar diversos trastornos y afecciones; el niraparib se distribuye con uniformidad sustancial por todo el vehículo farmacéuticamente aceptable de las formulaciones de cápsulas y presenta buenas propiedades de estabilidad a largo plazo y disolución.
MX2019011491A 2017-03-27 2018-03-27 Formulaciones de niraparib. MX2019011491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477425P 2017-03-27 2017-03-27
PCT/US2018/024597 WO2018183349A1 (en) 2017-03-27 2018-03-27 Niraparib formulations

Publications (1)

Publication Number Publication Date
MX2019011491A true MX2019011491A (es) 2020-01-23

Family

ID=63677008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011491A MX2019011491A (es) 2017-03-27 2018-03-27 Formulaciones de niraparib.

Country Status (14)

Country Link
US (2) US20200016142A1 (es)
EP (1) EP3606523A1 (es)
JP (1) JP2020512347A (es)
KR (1) KR20190130625A (es)
CN (1) CN110709083A (es)
AU (1) AU2018246213A1 (es)
BR (1) BR112019020191A2 (es)
CA (1) CA3058372A1 (es)
EA (1) EA201992162A1 (es)
IL (1) IL269621A (es)
MX (1) MX2019011491A (es)
SG (1) SG11201908977SA (es)
TW (1) TW201842908A (es)
WO (1) WO2018183349A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478286B1 (en) 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
KR20200118117A (ko) 2018-02-05 2020-10-14 테사로, 인코포레이티드 소아용 니라파립 제제 및 소아용 치료 방법
CA3087392A1 (en) 2019-07-16 2021-01-16 Apotex Inc. Crystalline forms of niraparib tosylate
MX2022009818A (es) * 2020-02-14 2022-09-05 Ksq Therapeutics Inc Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp).
CN116916895A (zh) * 2020-11-13 2023-10-20 辉瑞公司 他拉唑帕尼软明胶胶囊剂型
KR102306319B1 (ko) 2020-12-01 2021-09-30 주식회사 진원온원 포즈 추정 매핑 데이터를 생성하는 방법, 프로그램 및 컴퓨팅 장치
EP4429642A1 (en) * 2021-11-10 2024-09-18 Crititech, Inc. Niraparib particles and uses thereof
WO2023115795A1 (zh) * 2021-12-23 2023-06-29 深圳安泰维生物医药有限公司 一种核苷类化合物的晶型
CN119156216A (zh) 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
WO2025121315A1 (ja) * 2023-12-06 2025-06-12 旭化成株式会社 セルロース粉末及び成形体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606663D0 (en) * 2006-04-03 2006-05-10 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0700432D0 (en) * 2007-01-10 2007-02-21 Angeletti P Ist Richerche Bio Therapeutic compounds
NZ586675A (en) * 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
SI3317281T1 (sl) * 2015-07-02 2020-08-31 Acerta Pharma B.V. Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida

Also Published As

Publication number Publication date
KR20190130625A (ko) 2019-11-22
CA3058372A1 (en) 2018-10-04
EA201992162A1 (ru) 2020-02-28
TW201842908A (zh) 2018-12-16
CN110709083A (zh) 2020-01-17
US20200016142A1 (en) 2020-01-16
SG11201908977SA (en) 2019-10-30
WO2018183349A1 (en) 2018-10-04
US20210038585A1 (en) 2021-02-11
IL269621A (en) 2019-11-28
AU2018246213A1 (en) 2019-11-07
BR112019020191A2 (pt) 2020-04-22
EP3606523A1 (en) 2020-02-12
JP2020512347A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
MX2019011491A (es) Formulaciones de niraparib.
PH12020550341A1 (en) Niraparib formulations
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2019013954A (es) Inhibidores covalentes de kras.
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
PH12021551396A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.